

## SIERRA LEONE Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone					
<b>2. Grant number:</b> 1821-SLE-12d-X/ 09-SLE-8b-Y/18-SLE-25a-Y					
<b>3. Date of Decision Letter:</b> 5 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 4 doses per vial , LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2010 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2010-2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	26,859,476 <sup>3</sup>	1,594,000	2,593,000	2,689,000	33,735,476
<b>10. Vaccine introduction grant (in US\$):</b> A VIG of US\$ 100,00 was disbursed to Sierra Leone on 28 May 2010					
<b>11. Product switch grant:</b> Sierra Leone is eligible for a Product Switch Grant of US\$ 75,533 to support the PCV switch					
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2010-2018</b>		<b>2019</b>		
Number of Pneumococcal vaccines doses			474,000		
Annual Amounts (US\$)	26,859,476 <sup>5</sup>		1,594,000		
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
<b>14. Self-procurement:</b> N/A					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.

**15. Co-financing obligations:** Reference code: 1821-SLE-12d-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	34,200	62,400	64,800
Value of vaccine doses (US\$)	100,409	183,865	190,661
Total co-financing payments (US\$) (including freight)	102,000	186,500	193,000

**16. Operational support for campaigns:** Not applicable

**17. Additional reporting requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019  15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**18. Financial clarifications:** Not applicable

**19. Other conditions:** Not applicable

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
5 March 2019

## SIERRA LEONE Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone					
<b>2. Grant number:</b> 1821-SLE-04c-X					
<b>3. Date of Decision Letter:</b> 5 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine					
<b>6. Vaccine type:</b> Pentavalent					
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 doses per vial, LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2007 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2007-2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	17,536,797 <sup>3</sup>	387,500	498,000	516,000	18,938,297
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable					
<b>11. Product switch grant:</b> Not applicable					
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2007-2018</b>		<b>2019</b>		
Number of Pentavalent vaccines doses			544,000		
Annual Amounts (US\$)	17,536,797 <sup>5</sup>		387,500		
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
<b>14. Self-procurement:</b> Not applicable					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.

<p><b>15. Co-financing obligations:</b> Reference code: 1821-SLE-04c-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>									
<p><b>Type of supplies to be purchased with Country funds in each year</b></p>	<p><b>2019</b></p>	<p><b>2020</b></p>	<p><b>2021</b></p>						
Number of vaccine doses	213,000	274,000	284,000						
Value of vaccine doses (US\$)	146,858	188,762	195,746						
Total co-financing payments (US\$) (including freight)	151,500	195,000	202,000						
<p><b>16. Operational support for campaigns:</b> Not applicable</p>									
<p><b>17. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td> <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p> </td> <td> <p>To be agreed with Secretariat</p> </td> </tr> </tbody> </table>					Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>	<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>
	Due dates								
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>								
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>								
<p><b>18. Financial clarifications:</b> Not applicable</p>									
<p><b>19. Other conditions:</b> Not applicable</p>									

On behalf of Gavi



Hind Khatib-Othman  
 Managing Director, Country Programmes  
 5 March 2019

## SIERRA LEONE Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone					
<b>2. Grant number:</b> 1821-SLE-13b-X / 12-SLE-08a-Y					
<b>3. Date of Decision Letter:</b> 5 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine					
<b>6. Vaccine type:</b> Rotavirus					
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 doses schedule					
<b>8. Programme duration<sup>1</sup>:</b> 2012 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2012-2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	4,986,661 <sup>3</sup>	902,500	1,299,500	1,347,500	8,536,161
<b>10. Vaccine introduction grant (in US\$):</b> US\$ 193,500 disbursed on 6 May 2014					
<b>11. Product switch grant:</b> Not applicable					
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>Type of supplies to be purchased with Gavi funds in each year</b>	<b>2012-2018</b>		<b>2019</b>		
Number of Rotavirus vaccines doses			388,500		
Annual Amounts (US\$)	4,986,661 <sup>5</sup>		902,500		
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
<b>14. Self-procurement:</b> N/A					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.

**15. Co-financing obligations:** Reference code: 1821-SLE-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	37,500	54,000	55,500
Value of vaccine doses (US\$)	82,789	119,227	123,600
Total co-financing payments (US\$) (including freight)	85,500	123,000	127,500

**16. Operational support for campaigns:** N/A

**17. Additional reporting requirements:**

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**18. Financial clarifications:** N/A

**19. Other conditions:** N/A

On behalf of Gavi



Hind Khatib-Othman  
 Managing Director, Country Programmes  
 5 March 2019

## SIERRA LEONE Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone					
<b>2. Grant number:</b> 1821-SLE-06b-X					
<b>3. Date of Decision Letter:</b> 5 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013					
<b>5. Programme title:</b> NVS, Yellow Fever Routine					
<b>6. Vaccine type:</b> Yellow Fever					
<b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 doses per vial, LYOPHILISED					
<b>8. Programme duration<sup>1</sup>:</b> 2003 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2003-2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	3,087,452 <sup>3</sup>	381,500	392,000	412,500	4,273,452
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable					
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable): <sup>4</sup>					
<b>Type of supplies to be purchased with Gavi funds in each year</b>		<b>2003-2018</b>	<b>2019</b>		
Number of Yellow Fever vaccines doses			312,200		
Annual Amounts (US\$)		3,087,452 <sup>5</sup>	381,500		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2019 include the costs of injection safety devices. Annual amounts for 2019 onwards include only vaccine costs and freight.



<p><b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>																			
<p><b>13. Self-procurement:</b> N/A</p>																			
<p><b>14. Co-financing obligations: Reference code:</b> 1821-SLE-06b-X-C          According to the co-financing policy, the Country falls within the group Initial self-financing.          The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2019</th> <th>2020</th> <th>2021</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>61,200</td> <td>61,800</td> <td>65,000</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>71,543</td> <td>72,814</td> <td>76,629</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>75,000</td> <td>76,000</td> <td>80,000</td> </tr> </tbody> </table>				Type of supplies to be purchased with Country funds in each year	2019	2020	2021	Number of vaccine doses	61,200	61,800	65,000	Value of vaccine doses (US\$)	71,543	72,814	76,629	Total co-financing payments (US\$) (including freight)	75,000	76,000	80,000
Type of supplies to be purchased with Country funds in each year	2019	2020	2021																
Number of vaccine doses	61,200	61,800	65,000																
Value of vaccine doses (US\$)	71,543	72,814	76,629																
Total co-financing payments (US\$) (including freight)	75,000	76,000	80,000																
<p><b>15. Operational support for campaigns:</b> Not applicable</p>																			
<p><b>16. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>           To prepare for the annual procurement of vaccines, Country shall submit the following information each year:           <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td>           31 March 2019             15 May 2019         </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>					Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019  15 May 2019	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat										
	Due dates																		
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019  15 May 2019																		
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat																		



**17. Financial clarifications:** N/A

**18. Other conditions:** There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
5 March 2019

## SIERRA LEONE Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone			
<b>2. Grant number(s):</b> 19-SLE-25c-X / 15-SLE-08h-Y			
<b>3. Date of Decision Letter:</b> 5 March 2019			
<b>4. Date of the Partnership Framework Agreement:</b> 31 October 2013			
<b>5. Programme title:</b> NVS, IPV routine			
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)			
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 10 doses per vial, LIQUID			
<b>8. Programme duration<sup>2</sup>:</b> 2015 - 2019			
<b>9. Indicative Programme Budget:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2020 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2018	2019	Total <sup>3</sup>
Routine Programme (US\$)	224,061 <sup>4</sup>	931,500	1,155,561
Total Budget (US\$)	224,061	931,500	1,155,561
<b>10. Vaccine introduction grant:</b> US\$ 180,000 disbursed on 8 May 2015			
<b>11. Product switch grant:</b> Not applicable			
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>5</sup>			
	<b>2015-2018</b>	<b>2019</b>	
<b>Number of vaccines to be purchased with Gavi funds</b>			
IPV Routine Programme (doses)		406,300	
Annual Amounts (US\$)	224,061	931,500	
<b>13. Procurement agency:</b> UNICEF			

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2019.

<sup>4</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>5</sup> This is the amount that Gavi has approved.

<b>14. Self-procurement:</b> Not applicable	
<b>15. Co-financing obligations:</b> Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Sierra Leone is encouraged to contribute to vaccine and/or supply costs for IPV.	
<b>16. Operational support for catch-up campaigns:</b> Not applicable	
<b>17. Additional reporting requirements:</b>	
	<b>Due dates</b>
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019
	15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>18. Financial clarifications:</b> Not applicable	
<b>19. Other conditions:</b>	
<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Sierra Leone envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Sierra Leone.</p>	

On behalf of Gavi



Hind Khatib-Othman  
 Managing Director, Country Programmes  
 5 March 2019